# Bacterial Infections in Horses: Treatment Protocols

## Key Takeaways

- Bacterial infections in horses are diverse, with common pathogens including *Staphylococcus aureus*, *Streptococcus equi* subsp. *zooepidemicus*, *Escherichia coli*, and *Klebsiella pneumoniae*; zoonotic diseases like glanders (*Burkholderia mallei*) are notifiable.
- Diagnostic approaches integrate sample collection (tracheal wash, synovial fluid, blood), microbiological culture and sensitivity testing, molecular diagnostics (PCR for *Salmonella*, *C. difficile* toxins), and hematology/biochemistry to guide therapy.
- Empiric antimicrobial therapy for neonatal septicemia often involves ceftiofur and amikacin, while adult pneumonia may be treated with penicillin and gentamicin; targeted therapy refines choices based on susceptibility data, with beta-lactams for Gram-positives and aminoglycosides/cephalosporins for Gram-negatives.
- Treatment durations vary significantly, from 5-7 days for uncomplicated soft tissue infections to 4-8 weeks for septic arthritis, with clinical improvement and normalization of inflammatory markers guiding cessation.
- Antimicrobial resistance is a growing concern, necessitating strategies such as culturing and susceptibility testing, use of narrow-spectrum drugs, strict biosecurity, and adherence to dosage and duration guidelines to mitigate the emergence of resistant strains.
- Prevention relies on vaccination (e.g., for strangles, tetanus), rigorous biosecurity measures including isolation and disinfection, prompt and thorough wound management, and ensuring adequate passive immunity in foals through colostrum intake.

---

## Introduction

Bacterial infections in horses represent a significant proportion of equine medical cases, ranging from superficial skin wounds to life threatening septicemia and pneumonia [<a href="#ref-1">1</a>, <a href="#ref-2">2</a>]. Effective management of these infections requires a thorough understanding of the causative pathogens, their antimicrobial susceptibility patterns, and the pharmacokinetic principles governing drug distribution in equine tissues [<a href="#ref-3">3</a>]. This article provides a systematic review of treatment protocols for common bacterial infections in horses, with emphasis on evidence based therapeutic decision making and antimicrobial stewardship.

## Etiology and Epidemiology

Horses are susceptible to a diverse array of bacterial pathogens. The most frequently isolated organisms include Gram-positive cocci such as *Staphylococcus aureus* and *Streptococcus equi* subsp. *zooepidemicus*, Gram-negative rods including *Escherichia coli*, *Actinobacillus equuli*, and *Klebsiella pneumoniae*, and obligate anaerobes like *Clostridium difficile* and *Bacteroides fragilis* [<a href="#ref-1">1</a>, <a href="#ref-4">4</a>]. Zoonotic pathogens of regulatory concern, such as *Burkholderia mallei* (the agent of glanders) and *Brucella abortus*, remain notifiable diseases in many regions [<a href="#ref-5">5</a>].

The epidemiology of equine bacterial infections is influenced by environmental factors (e.g., housing, bedding, pasture hygiene), host immune status, and concurrent viral or parasitic diseases [<a href="#ref-2">2</a>]. Foals are particularly vulnerable to Gram-negative septicemia during the first days of life, while adult horses commonly present with bacterial respiratory infections following stress or viral respiratory disease [<a href="#ref-1">1</a>, <a href="#ref-6">6</a>]. Wound contamination, surgical site infections, and gastrointestinal disorders (e.g., colitis) are additional frequent contexts for bacterial overgrowth and invasion [<a href="#ref-3">3</a>].

## Clinical Signs and Pathology

Clinical manifestations depend on the affected organ system and the virulence of the bacterial strain.

**Respiratory tract:** Bacterial pneumonia in horses typically presents with fever, tachypnea, purulent nasal discharge, cough, and abnormal lung auscultation findings (crackles, wheezes, or dullness) [<a href="#ref-1">1</a>, <a href="#ref-6">6</a>]. Abscessation within the pulmonary parenchyma may occur with *S. equi* subsp. *zooepidemicus*, leading to chronic weight loss and exercise intolerance [<a href="#ref-2">2</a>].

**Gastrointestinal tract:** Enteric infections caused by *Salmonella* spp., *C. difficile*, or *E. coli* (especially in foals) result in acute diarrhea, dehydration, endotoxemia, and acid base disturbances [<a href="#ref-4">4</a>, <a href="#ref-7">7</a>]. *C. difficile* infection is strongly associated with prior antimicrobial use, disrupting the normal colonic microbiota and allowing toxin producing strains to proliferate [<a href="#ref-7">7</a>].

**Musculoskeletal system:** Septic arthritis and osteomyelitis are common sequelae of hematogenous bacterial dissemination in foals or penetrating wounds in adults [<a href="#ref-1">1</a>, <a href="#ref-8">8</a>]. Synovial fluid analysis reveals elevated total protein, nucleated cell counts (>10,000 cells/µL with >90% neutrophils), and bacteria on Gram stain or culture [<a href="#ref-8">8</a>].

**Skin and soft tissue:** Abscesses, cellulitis, and purulent dermatitis are frequently caused by *S. aureus* or *Streptococcus* spp. [<a href="#ref-3">3</a>]. Wound infections may progress to deep fascial involvement if not managed promptly.

**Reproductive tract:** Bacterial endometritis, placentitis, and metritis in mares are predominantly associated with *Streptococcus equi* subsp. *zooepidemicus*, *E. coli*, and *Klebsiella pneumoniae* [<a href="#ref-1">1</a>, <a href="#ref-9">9</a>]. Ascending infections from the lower genital tract lead to early embryonic death, abortion, or neonatal sepsis in foals.

## Diagnostic Approaches

Accurate etiologic diagnosis is essential for rational antimicrobial selection. Recommended diagnostic steps include:

1. **Sample collection:** Aseptically obtained specimens from the suspected infection site, such as tracheal wash fluid, bronchoalveolar lavage, synovial fluid, abscess aspirates, urine, or blood [<a href="#ref-2">2</a>, <a href="#ref-4">4</a>]. Fecal samples are indicated for enteric pathogens, with selective enrichment cultures for *Salmonella* spp. [<a href="#ref-7">7</a>].

2. **Microbiological culture and sensitivity:** Aerobic and anaerobic culture on appropriate media (blood agar, [MacConkey agar](/knowledge/diagnostics/microbiology/macconkey-agar-selective-differential-enteric), selective media) [<a href="#ref-1">1</a>]. Antimicrobial susceptibility testing using disk diffusion or broth microdilution methods should follow Clinical and Laboratory Standards Institute (CLSI) guidelines for veterinary isolates [<a href="#ref-3">3</a>].

3. **Molecular diagnostics:** Polymerase chain reaction (PCR) assays are available for rapid detection of *Salmonella* spp., *C. difficile* toxins A and B, and *S. equi* subsp. *equi* (strangles) [<a href="#ref-4">4</a>, <a href="#ref-6">6</a>]. Real-time PCR can provide results within hours, expediting isolation and treatment decisions.

4. **Hematology and biochemistry:** Complete blood count often reveals leukocytosis with neutrophilia and a left shift; fibrinogen and serum amyloid A are elevated in systemic inflammation [<a href="#ref-1">1</a>]. Serum biochemical profiling assesses organ function and guides supportive care.

5. **Imaging:** Thoracic radiography aids diagnosis of pneumonia and lung abscesses. Ultrasonography is useful for detecting pleural effusion, abdominal abscesses, and synovial fluid changes [<a href="#ref-2">2</a>, <a href="#ref-6">6</a>].

The following Mermaid diagram outlines an integrated diagnostic and therapeutic decision algorithm for suspected bacterial infections in horses.

```mermaid
flowchart TD
 A["Clinical suspicion of bacterial infection"] --> B["Sample collection: sterile site"]
 B --> C["Gram stain & cytology"]
 C --> D["Culture & sensitivity"]
 D --> E{"Results available?"}
 E -->|"Yes"| F["Targeted antimicrobial therapy based on MIC"]
 E -->|"No"| G["Empiric therapy based on likely pathogen"]
 G --> H["Reassess in 48-72 hours"]
 H --> I["Clinical improvement?"]
 I -->|"Yes"| J["Continue therapy for appropriate duration"]
 I -->|"No"| K["Re-culture & sensitivity, adjust treatment"]
 K --> F
 F --> L["Monitor for adverse effects & antimicrobial resistance"]
 L --> M["Complete prescribed course"]
```

## Treatment Protocols for Horse Bacterial Infection

Treatment protocols for horse bacterial infection require careful consideration of the pathogen, infection site, host factors (age, weight, renal/hepatic function), and local antimicrobial resistance patterns [<a href="#ref-3">3</a>]. The following subsections detail evidence based empiric and targeted regimens.

### Empiric Antimicrobial Selection

Empiric therapy is initiated before culture results become available. Table 1 summarizes recommended empiric choices for common equine bacterial infections.

**Table 1. Empiric antimicrobial protocols for selected equine bacterial infections.**

| Infection type | Likely pathogens | First line antimicrobial | Dose (adult horse, IV/IM/PO) | Comments |
|--------|---------|-------------|---------------|-----|
| Neonatal septicemia | *E. coli*, *Actinobacillus equuli*, *Klebsiella* spp., Gram-positive cocci | Ceftiofur sodium (IV) + amikacin (IV) | Ceftiofur 2.2 mg/kg q12h; amikacin 15 mg/kg q24h | Monitor renal function; adjust aminoglycoside dose based on trough levels [<a href="#ref-1">1</a>] |
| Adult pneumonia | *S. zooepidemicus*, *E. coli*, *Pasteurella* spp. | Potassium penicillin G (IV) + gentamicin (IV) | Penicillin 22,000 IU/kg q6h; gentamicin 6.6 mg/kg q24h | Gentamicin is nephrotoxic; use only if hydration status is adequate [<a href="#ref-2">2</a>, <a href="#ref-6">6</a>] |
| Strangles (uncomplicated) | *S. equi* subsp. *equi* | Procaine penicillin G (IM) | 22,000 IU/kg q12h | Avoid NSAIDs that mask abscess formation; surgical drainage if needed [<a href="#ref-4">4</a>] |
| Septic arthritis | Gram-positive cocci, Gram-negative rods | Ceftiofur (IV) or enrofloxacin (PO/IV) | Ceftiofur 2.2 mg/kg q12h; enrofloxacin 7.5 mg/kg q24h | Enrofloxacin should be avoided in foals due to cartilage damage risk [<a href="#ref-8">8</a>] |
| Colitis (suspected *C. difficile*) | *C. difficile* | Metronidazole (PO) | 15 mg/kg q6-8h | Discontinue inciting antimicrobials; fluid therapy and probiotic support [<a href="#ref-7">7</a>] |
| Endometritis | *S. zooepidemicus*, *E. coli* | Intrauterine infusion (e.g., ceftiofur) | Variable depending on product | Culture and sensitivity essential before treatment; consider systemic antimicrobials if ascending infection [<a href="#ref-9">9</a>] |

### Targeted Therapy Based on Pathogen

Once bacterial identification and susceptibility data are available, antimicrobial selection should be refined to a narrow spectrum when possible [<a href="#ref-3">3</a>].

**Gram-positive infections:** *Streptococcus* spp. remain susceptible to beta-lactam antibiotics. Penicillin G (22,000 IU/kg IV q6h or procaine penicillin 22,000 IU/kg IM q12h) is the treatment of choice [<a href="#ref-1">1</a>, <a href="#ref-4">4</a>]. For *Staphylococcus* spp. that produce beta-lactamase, first generation cephalosporins (cefazolin 20 mg/kg IV q8h) or potentiated sulfonamides (trimethoprim sulfamethoxazole 30 mg/kg PO q12h) are effective alternatives [<a href="#ref-3">3</a>]. Vancomycin should be reserved for multidrug resistant *S. aureus* (MRSA) and used under strict guidance [<a href="#ref-2">2</a>].

**Gram-negative infections:** Aminoglycosides (gentamicin, amikacin) are potent agents but require therapeutic drug monitoring to avoid nephrotoxicity and ototoxicity [<a href="#ref-1">1</a>]. Third generation cephalosporins (ceftiofur, cefotaxime) provide broad Gram-negative coverage with lower toxicity [<a href="#ref-6">6</a>]. Fluoroquinolones (enrofloxacin, marbofloxacin) are effective against *E. coli* and *Klebsiella* but should not be used in young foals due to arthropathy risk [<a href="#ref-8">8</a>]. Extended spectrum beta-lactams such as ticarcillin clavulanic acid may be required for resistant *Pseudomonas* or *Enterobacter* infections [<a href="#ref-2">2</a>].

**Anaerobic infections:** Metronidazole (15 mg/kg PO q6-8h) remains the drug of choice for *Clostridium* spp. and *Bacteroides* infections [<a href="#ref-7">7</a>]. Penicillin G also covers many oral anaerobes except those producing beta-lactamase. In severe abdominal infections, combination therapy with an aminoglycoside or fluoroquinolone is often indicated.

### Duration of Therapy

Recommended durations vary. For uncomplicated soft tissue infections, 5 to 7 days of treatment is often sufficient [<a href="#ref-3">3</a>]. Pneumonia typically requires 10 to 14 days of therapy, with clinical improvement (fever resolution, neutrophilia normalization) guiding cessation [<a href="#ref-2">2</a>, <a href="#ref-6">6</a>]. Septic arthritis may require 4 to 8 weeks of antimicrobial therapy combined with joint lavage and synovectomy [<a href="#ref-8">8</a>]. Fecal shedding of *Salmonella* should be monitored; antimicrobial treatment of asymptomatic carriers is not recommended [<a href="#ref-4">4</a>].

## Antimicrobial Stewardship and Resistance

Antimicrobial resistance (AMR) in equine pathogens is an emerging concern. Methicillin resistant *S. aureus* (MRSA), extended spectrum beta-lactamase (ESBL) producing *E. coli*, and multidrug resistant *[Pseudomonas aeruginosa](/knowledge/bacteria/gram-negative/pseudomonas-aeruginosa-multidrug-resistance-biofilms)* have been documented in hospital and community equine settings [<a href="#ref-2">2</a>, <a href="#ref-3">3</a>]. Strategies to mitigate AMR include:

- Culturing and susceptibility testing before initiating long term therapy [<a href="#ref-1">1</a>].
- Using narrow spectrum drugs when possible [<a href="#ref-3">3</a>].
- Avoiding prophylactic antimicrobials in clean surgical procedures [<a href="#ref-2">2</a>].
- Implementing biosecurity measures to prevent cross contamination with resistant strains [<a href="#ref-4">4</a>].
- Adhering to dosage and duration guidelines to avoid subtherapeutic exposure [<a href="#ref-3">3</a>].

## Control and Prevention

Prevention of bacterial infections in horses relies on vaccination, biosecurity, and prudent management.

**Vaccination:** Licensed vaccines are available for *S. equi* subsp. *equi* (strangles), tetanus (*Clostridium tetani*), and some *Leptospira* serovars [<a href="#ref-1">1</a>, <a href="#ref-4">4</a>]. Vaccine efficacy is variable; strangles vaccines may reduce severity but do not prevent all infections.

**Biosecurity:** Isolation of sick horses, disinfection of contaminated equipment, and hand hygiene between patients reduce pathogen transmission [<a href="#ref-2">2</a>]. Routine culture screening of incoming horses for *Salmonella* or MRSA may be indicated in high risk facilities.

**Wound management:** Immediate cleaning, debridement, and protective bandaging reduce the incidence of secondary bacterial infection [<a href="#ref-3">3</a>]. Tetanus prophylaxis is essential for all puncture wounds.

**Foal management:** Ensuring adequate colostrum intake (immunoglobulin G > 800 mg/dL) provides passive immunity against Gram-negative septicemia [<a href="#ref-1">1</a>]. Minimizing environmental contamination in foaling areas reduces exposure to opportunistic pathogens.

## References

<a id="ref-1"></a>[<a href="#ref-1">1</a>] Sellon DC, Long MT. [Equine Infectious Diseases](/knowledge/veterinary-medicine/equine-care/equine-infectious-diseases-viral-bacterial-fungal). 2nd ed. Saunders Elsevier; 2013.

<a id="ref-2"></a>[<a href="#ref-2">2</a>] Reed SM, Bayly WM, Sellon DC. Equine Internal Medicine. 4th ed. Elsevier; 2017.

<a id="ref-3"></a>[<a href="#ref-3">3</a>] Bertone JJ. Clinical Equine Pharmacology. W.B. Saunders; 2001.

<a id="ref-4"></a>[<a href="#ref-4">4</a>] Sweeney CR, Boles CL, Smith BP. Bacterial diseases. In: Smith BP, ed. Large Animal Internal Medicine. 6th ed. Mosby; 2019.

<a id="ref-5"></a>[<a href="#ref-5">5</a>] World Organisation for Animal Health (OIE). Chapter 3.6.1: Glanders. In: Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. OIE; 2018.

<a id="ref-6"></a>[<a href="#ref-6">6</a>] Ainsworth DM, Weldon AD, Wooden BG. Bacterial pneumonia in horses: diagnosis and treatment. Compend Contin Educ Vet. 2004;26(1):51-60.

<a id="ref-7"></a>[<a href="#ref-7">7</a>] Weese JS, Arroyo L, Staempfli HR. Clostridium difficile associated disease in horses. Equine Vet Educ. 2006;18(3):159-166.

<a id="ref-8"></a>[<a href="#ref-8">8</a>] Baxter GM. Equine septic arthritis: diagnosis and treatment. Vet Clin North Am Equine Pract. 2000;16(2):269-286.

<a id="ref-9"></a>[<a href="#ref-9">9</a>] Troedsson MHT, Woodward EM. Bacterial endometritis in mares. Equine Vet Educ. 2016;28(10):562-569.

## Related Clinical & Scientific Guides

* [Duck Diseases: A Comprehensive Overview for Veterinary Practitioners](/knowledge/bacteria/avian-bacteria/duck-diseases-comprehensive-overview-veterinary)
* [Salmonella Dublin in Cattle: Emerging Pathogen, Diagnostic Challenges, and Public Health Impact](/knowledge/bacteria/livestock-bacteria/salmonella-dublin-cattle-emerging-pathogen-diagnostic-public-health)
* [Mycoplasma Infections in Poultry: Vaccination Strategies and Control Programs](/knowledge/bacteria/avian-bacteria/mycoplasma-infections-in-poultry-vaccination-strategies-and-control-programs)